Drugs / Rapastinel
Rapastinel
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03814733 | Nov 2018 → Mar 2019 | — | Naurex, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03799900 | Nov 2018 → Mar 2019 | substance abuse | Naurex, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01014650 | Nov 2009 → Oct 2015 | — | Naurex, Inc | Completed | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT03352453 | Dec 2017 → Jun 2019 | major depressive disorder | Naurex, Inc | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02267629 | Oct 2014 → Feb 2016 | obsessive-compulsive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT02192099 | Sep 2014 → Nov 2018 | major depressive disorder | Naurex, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT01844726 | May 2013 → Jan 2016 | psychiatric disorder | Northwestern University | Terminated | Missed primary |
| Phase 2 | NCT01684163 | Nov 2012 → Apr 2014 | major depressive disorder | Naurex, Inc | Completed | No outcome recorded |
| Phase 2 | NCT01234558 | May 2011 → Jun 2012 | major depressive disorder | Naurex, Inc | Completed | No outcome recorded |
| Phase 310 trials · 4 missed | ||||||
| Phase 3 | NCT03855865 | Jul 2019 → Dec 2020 | major depressive disorder | Naurex, Inc | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03675776 | Oct 2018 → Jul 2019 | major depressive disorder | Naurex, Inc | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03668600 | Aug 2018 → Jul 2019 | major depressive disorder | Naurex, Inc | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03614156 | Aug 2018 → Jul 2019 | major depressive disorder | Naurex, Inc | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03560518 | Jun 2018 → Jul 2019 | major depressive disorder | Naurex, Inc | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03002077 | Feb 2017 → Dec 2018 | major depressive disorder | Naurex, Inc | Completed | No outcome recorded |
| Phase 3 | NCT02951988 | Nov 2016 → Feb 2019 | major depressive disorder | Naurex, Inc | Completed | Missed primary |
| Phase 3 | NCT02943577 | Nov 2016 → Oct 2018 | major depressive disorder | Naurex, Inc | Completed | Missed primary |
| Phase 3 | NCT02943564 | Nov 2016 → Dec 2018 | major depressive disorder | Naurex, Inc | Completed | Missed primary |
| Phase 3 | NCT02932943 | Oct 2016 → Sep 2018 | major depressive disorder | Naurex, Inc | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-03-06 | AbbVie | Results Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD) abbvie.com ↗
In three acute studies (RAP-MD-01,-02,-03), the rapastinel treatment arms did not differentiate from placebo on the primary and key secondary endpoints. |
| 2019-01-03 | AbbVie | Results New Data Published in the International Journal of Neuropsychopharmacology Support that Rapastinel May Produce Rapid and Sustained Antidepressant Effects Through a Potentially Novel Mechanism of Action abbvie.com ↗
Preclinical research demonstrated rapastinel positively modulates the NMDA receptor |
All press releases naming this drug 2 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rapastinel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03799900 ↗ |
| Known as | GLYX-13 | “10 mg/kg IV Rapastinel (formerly GLYX-13)” NCT02267629 ↗ |
| Known as | Rapastinelum | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544917 ↗ |
| Known as | Tppt-amide | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544917 ↗ |
| Action | Activate | “NMDA receptor glycine site functional partial agonist” NCT01014650 ↗ |
| Modality | Other / unclassified | “N-methyl-D-aspartate ionotropic glutamatergic receptor (NMDAR) modulators, including rapastinel and ketamine” PMID 34423904 ↗ Nov 2021 |
| Route | Intravenous | “single IV or SC dose” NCT01014650 ↗ |
| Route | Subcutaneous | “single IV or SC dose” NCT01014650 ↗ |